| Autor: |
Marc D. Moncrieff, Serigne N. Lo, Richard A. Scolyer, Martin J. Heaton, Jenny P. Nobes, Andrew P. Snelling, Michael J. Carr, Carolyn Nessim, Ryckie Wade, A. Howard Peach, Rumi Kisyova, Jennifer Mason, Ewan D. Wilson, Grant Nolan, Rowan Pritchard Jones, Iva Johansson, Roger Olofsson Bagge, Lucie J. Wright, Nakul G. Patel, Vernon K. Sondak, John F. Thompson, Jonathan S. Zager |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(34) |
| ISSN: |
1527-7755 |
| Popis: |
PURPOSE Indications for offering adjuvant systemic therapy for patients with early-stage melanomas with low disease burden sentinel node (SN) micrometastases, namely, American Joint Committee on Cancer (AJCC; eighth edition) stage IIIA disease, are presently controversial. The current study sought to identify high-risk SN-positive AJCC stage IIIA patients who are more likely to derive benefit from adjuvant systemic therapy. METHODS Patients were recruited from an intercontinental (Australia/Europe/North America) consortium of nine high-volume cancer centers. All were adult patients with pathologic stage pT1b/pT2a primary cutaneous melanomas who underwent SN biopsy between 2005 and 2020. Patient data, primary tumor and SN characteristics, and survival outcomes were analyzed. RESULTS Three thousand six hundred seven patients were included. The median follow-up was 34 months. Pairwise disease comparison demonstrated no significant survival difference between N1a and N2a subgroups. Survival analysis identified a SN tumor deposit maximum dimension of 0.3 mm as the optimal cut point for stratifying survival. Five-year disease-specific survival rates were 80.3% and 94.1% for patients with SN metastatic tumor deposits ≥ 0.3 mm and < 0.3 mm, respectively (hazard ratio, 1.26 [1.11 to 1.44]; P < .0001). Similar findings were seen for overall disease-free and distant metastasis-free survival. There were no survival differences between the AJCC IB patients and low-risk (< 0.3 mm) AJCC IIIA patients. The newly identified high-risk (≥ 0.3 mm) subgroup comprised 271 (66.4%) of the AJCC IIIA cohort, whereas only 142 (34.8%) patients had SN tumor deposits > 1 mm in maximum dimension. CONCLUSION Patients with AJCC IIIA melanoma with SN tumor deposits ≥ 0.3 mm in maximum dimension are at higher risk of disease progression and may benefit from adjuvant systemic therapy or enrollment into a clinical trial. Patients with SN deposits < 0.3 mm in maximum dimension can be managed similar to their SN-negative, AJCC IB counterparts, thereby avoiding regular radiological surveillance and more intensive follow-up. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
